Elanco Reports the First Shipment of Varenzin-CA1 for Anemia associated with CKD in Felines within the US
Shots:
- The company launches Varenzin-CA1 (molidustat OS) as the first and only treatment to control non-regenerative anemia in cats with CKD in veterinary clinics
- Varenzin-CA1 showed a reasonable expectation of efficacy in managing anemia in CKD cats. By Days 28 & 56, 50% & 75% of cats had elevated red blood cell counts thus improving the ability to deliver necessary oxygen and nutrients to their bodies
- Varenzin-CA1 received conditional approval from the US FDA for the management of nonregenerative anemia in cats with CKD. Elanco’s existing feline portfolio, incl. Elura (capromorelin OS) for the management of weight loss in cats with CKD
Ref: Elanco | Image: Elanco
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
